CAR T-Cell Therapy Sends Multiple Myeloma Into Lasting Remission (Abstract LBA3001)
CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ̶ chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. Read the full release.
Thanks, great article.